Tue, Mar 31st 2026, 5:00 PM

Tue, Mar 31st 2026, 5:00 PM
Developing an efficient purification process for adeno-associated viral vectors (AAVs) is crucial for the success of new drugs during the investigational phase and throughout the product development lifecycle. Optimizing the AAV purification process early on can significantly reduce costs for clients and patients once large-scale production is established. We will present screening for the separation of empty and full AAVs using three different CIM QA HR formats and explain how we can scale them to process scale.
Key Learning Objectives:
Speakers:
Marko Narobe, Product Manager for High-Throughput Solutions at Sartorius BIA Separations
Sara Drmota Prebil, PhD, Process Development Manager at Sartorius BIA Separations
Nicholas Pearman, PhD, Senior Scientist at Pharmaron Biologics UK Ltd.

Create an account now for exclusive benefits, personalized recommendations, and seamless order tracking. Elevate your lab experience today!